Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Serametrix Testing Lab Gains CLIA Certification

Serametrix Testing Lab Gains CLIA Certification

Oct 03, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Serametrix, a San Diego-based company specializing in immune monitoring assays, has received CLIA certification for its laboratory in Carlsbad, California, the firm said recently.

The certification enables the company to offer its myeloid-derived suppressor cell assay for cancer patients. The flow cytometry-based assay was developed at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center and was licensed by Serametrix in 2013.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

What's Popular?

In Cancer

  1. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  2. Deepcell Advancing AI-Driven Cell Morphology Tech for Single-Cell Genomics, Liquid Biopsy

    Premium

  3. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  4. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  5. C2i Genomics Acquires Sequencing Lab QNA Dx

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.